Cecal 내고의 찔린 절차

Executive Industry Relevance

The cecal ligation and puncture (CLP) model provides a reproducible, polymicrobial sepsis model that mirrors human pathophysiology, enabling target validation and mechanistic de-risking in early discovery. By reproducing both hyperdynamic and hypodynamic phases, it supports predictive confidence in therapeutic screening and translational biomarker identification. This model aids in assessing drug efficacy across disease stages, reducing late-stage failure risk in sepsis-related programs.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of immunological and physiological status across sepsis phases to validate therapeutic hypotheses.
• Operational Value: Supports functional target validation by modeling cytokine profiles and lymphocyte apoptosis relevant to human sepsis.
• Scientific Value: Facilitates pathway clarification through controlled induction of polymicrobial infection and organ damage readouts.

Screening & Assay Development

• Scientific Value: Generates quantifiable immune response and organ dysfunction metrics for assay standardization.
• Operational Value: Provides reproducible survival and physiological readouts enabling reliable compound evaluation.
• Scientific Value: Allows modulation of sepsis severity via ligation length, puncture number, and needle thickness for dose-response screening.

Translational & Preclinical Research

• Scientific Value: Models disease-relevant immune depression and nocosomial infection risk for translational biomarker alignment.
• Operational Value: Supports preclinical continuity by replicating clinical sepsis progression from hyperdynamic to hypodynamic phases.
• Scientific Value: Enables risk-adjusted advancement decisions through measurable outcomes like body temperature drop and lethargy.

Pipeline & Workflow Integration

The CLP model fits within the discovery continuum from target validation through lead identification to preclinical efficacy testing, particularly for immunomodulatory agents.

• Discovery Biology: Supports hypothesis testing by modeling systemic inflammatory response and immunosuppression phases.
• Screening: Delivers quantitative outputs such as cytokine levels, organ injury markers, and survival rates for compound comparison.
• Analytics: Enables statistical analysis of time-to-event and physiological parameters to assess treatment effects.
• Translational Research: Connects to preclinical validation via replicated human sepsis cytokine profiles and organ failure patterns.
• Enterprise Reuse: Serves as a reusable platform for sepsis mechanism probing and therapeutic screening across multiple campaigns.

Operational & Enterprise Impact

• Scientific Value: Predictive confidence in target validation through phase-specific pathophysiological modeling.
• Operational Value: Standardization via controlled severity modulation and postoperative monitoring protocols.
• Strategic Value: Improved go/no-go decisions by capturing stage-dependent drug effects in sepsis.
• Portfolio Impact: Risk-adjusted prioritization based on model reproducibility and translational fidelity.

Implementation Considerations

• Requires expertise in aseptic surgical technique and rodent anesthesia.
• Dependent on instrumentation for ligation, puncture, and postoperative monitoring.
• Necessitates cross-team standardization of severity scoring and resuscitation protocols.
• Adaptation considerations include mouse strain, sex, and baseline health status.
• Practical limitations include variability in fecal extrusion and model mortality rates.

Biopharma FAQs